HolderBook

Catalio Capital Management, LP

Reported holdings as of Q2 2026, from 7 quarterly filings.

CIK
1958125
Reported value
$532.1M
Positions
39
Top 10 weight
56.7%
Filed
2026-08-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
AVALYN PHARMACEUTICALS INCAVLN$55.2M1,675,83010.37%-newNEW
JOHNSON & JOHNSONJNJ$35.3M138,9466.63%-newNEW
GILEAD SCIENCES INCGILD$34.0M269,3096.39%+1.62pp3q+64.3%+$13.3M
BRIDGEBIO PHARMA INCBBIO$33.9M455,0416.37%-0.33pp2q+5.3%+$1.7M
SYNDAX PHARMACEUTICALS INCSNDX$26.6M1,215,6984.99%-0.10pp6q+16.5%+$3.8M
DEFINIUM THERAPEUTICS INCDFTX$26.5M562,6724.97%+0.88pp2q-45.8%-$22.4M
BRISTOL-MYERS SQUIBB COBMY$23.8M412,9614.47%-0.86pp3q-1.8%-$447.5K
PARABILIS MEDICINES INCPBLS$22.6M824,0434.24%-newNEW
NATERA INCNTRA$22.3M82,1814.19%+1.23pp5q+15.9%+$3.1M
INCYTE CORPINCY$21.7M191,6274.08%+0.50pp2q+5.2%+$1.1M
SEPTERNA INCSEPN$18.0M536,1523.37%+1.90pp7q+82.1%+$8.1M
MINERALYS THERAPEUTICS INCMLYS$17.5M648,7223.29%+0.80pp3q+47.8%+$5.7M
HEARTFLOW INCHTFL$17.1M583,0553.21%+1.16pp3q+44.5%+$5.3M
CORVUS PHARMACEUTICALS INCCRVS$16.1M1,080,8883.03%+0.31pp2q+21.2%+$2.8M
STRUCTURE THERAPEUTICS INCGPCR$14.8M276,5502.79%+0.22pp7q+8.3%+$1.1M
PROTAGONIST THERAPEUTICS INCPTGX$13.1M106,7992.46%-newNEW
DISC MEDICINE INCIRON$11.7M159,3842.19%+0.55pp5q+29.6%+$2.7M
EDWARDS LIFESCIENCES CORPEW$11.3M124,7782.12%-0.30pp3q-13.7%-$1.8M
AXSOME THERAPEUTICS INCAXSM$10.6M43,1821.99%-newNEW
ULTRAGENYX PHARMACEUTICAL INRARE$10.6M316,2521.98%-1.74pp5q-62.8%-$17.8M
KAILERA THERAPEUTICS INCKLRA$10.3M468,7501.94%-newNEW
KARYOPHARM THERAPEUTICS INCKPTI$9.2M940,8551.73%+0.68pp6q+4.8%+$421.5K
ODYSSEY THERAPEUTICS INCODTX$8.6M457,8391.61%-newNEW
ASCENDIS PHARMA A/SASND$8.5M31,7591.59%-newNEW
KARDIGAN INCKARD$7.5M312,5001.40%-newNEW
ELEDON PHARMACEUTICALS INCELDN$6.7M1,695,0711.26%+0.20pp4q+3.4%+$217.7K
4D MOLECULAR THERAPEUTICS INFDMT$6.3M471,2541.18%-newNEW
VERADERMICS INCMANE$5.6M45,8561.06%-1.23pp2q-73.6%-$15.7M
DYNE THERAPEUTICS INCDYN$5.4M244,9291.02%-0.05pp3q-13.4%-$844.5K
FRACTYL HEALTH INCGUTS$4.9M6,168,7490.92%+0.40pp7q+12.3%+$537.7K
IMMUNOCORE HLDGS PLCIMCR$4.7M148,0450.88%+0.35pp2q+75.5%+$2.0M
DIANTHUS THERAPEUTICS INCDNTH$3.2M32,9410.60%-9.22pp7q-94.1%-$51.4M
BRIDGEBIO ONCOLOGY THERAPEUTBBOT$2.4M318,4070.46%-newNEW
PROTARA THERAPEUTICS INCTARA$2.0M520,1480.37%-0.26pp7q-10.3%-$228.7K
HYPERFINE INCHYPR$1.8M1,320,0410.33%+0.04pp7qHELD
ATAIBECKLEY INCATAI$1.0M196,8580.19%+0.05pp2qHELD
METAGENOMI THERAPEUTICS INCMGX$629.5K528,9930.12%-0.03pp7qHELD
OUTSET MED INCOM$511.0K118,2790.10%flat6qHELD
FAETH THERAPEUTICS INCFTH$367.9K14,7180.07%-0.03pp5qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 69.6%Medical Devices 6.7%Healthcare Services 4.2%Not classified 19.6%
 
SectorValueShare
Biotech & Pharma$370.1M69.6%
Medical Devices$35.6M6.7%
Healthcare Services$22.3M4.2%
Not classified$104.1M19.6%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$532.1M39111581356.7%45
Q1 2026$478.7M411012131454.5%45
Q4 2025$565.8M4514520751.2%48
Q3 2025$540.9M381010131255.9%45
Q2 2025$476.9M40138131062.5%45
Q1 2025$411.1M3714761068.3%45
Q4 2024$457.1M33000057.3%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.